John C Krauss, MD

I am the medical director of the multidisciplinary colorectal clinic, and I actively lead therapeutic clinical trials at the University of Michigan. I work with the Southwest Oncology Group, the NSABP Foundation, and pharmaceutical sponsors to make promising clinical trials available for my patients. I am actively working on eliminating surgery for selected patients with rectal cancer. I am interested in improving communication with my patients so they can get the optimum care for complex conditions.

The major focus of my research is experimental therapeutics of cancer. I have enrolled patients in FDA registration trials of irinotecan, nab-paclitaxel, regorafenib, and I have been the site principal investigator on the FDA registration trials of entrectinib, and NTRK and ROS1 inhibitor, sotorasib, a KRASG12c inhibitor, and fruquintinib, a VEGF inhibitor. I was the site principal investigator on the organ preservation of rectal cancer trial, which demonstrated that giving combined modality chemotherapy radiation therapy prior to systemic treatment improves the complete response rate of the tumor, so fewer patients need to have an operation.